Using clinicaltrials.gov to understand the state of clinical research in pulmonary, critical care, and sleep medicine

Annals of the American Thoracic Society

Volumn 10, Issue 5, 2013, Pages 411-417

  Todd, Jamie L ^a,b   White, Kyle R ^b   Chiswell, Karen ^b   Tasneem, Asba ^b   Palmer, Scott M ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Clinical research; ClinicalTrials.gov; Trial registry

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE;

ARTICLE; ASTHMA; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DATA BASE; DRUG SAFETY; HUMAN; INTENSIVE CARE; LUNG FUNCTION; MORTALITY; ONCOLOGY; OPEN STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONOLOGY; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE; SEPSIS; SHOCK; SLEEP MEDICINE; STATISTICS;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; CRITICAL CARE; DATABASES, FACTUAL; HUMANS; PULMONARY MEDICINE; REGISTRIES; SLEEP MEDICINE SPECIALTY;

EID: 84892179744     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201305-111OC     Document Type: Article

References (20)

1. Kochanek KD, Xu J, Murphy SL, Miniño AM, Kung H-C. Deaths: preliminary data for 2009. Natl Vital Stat Rep 2011;59:1-51.
2. Angus DC, Kelley MA, Schmitz RJ, White A, Popovich J Jr.; Committee on Manpower for Pulmonary and Critical Care Societies (COMPACCS). Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: can we meet the requirements of an aging population? JAMA 2000;284:2762-2770.
3. Kiley JP. Advancing respiratory research. Chest 2011;140:497-501.
4. Sung NS, Crowley WF Jr., Genel M, Salber P, Sandy L, Sherwood LM, Johnson SB, Catanese V, Tilson H, Getz K, et al. Central challenges facing the national clinical research enterprise. JAMA 2003;289: 1278-1287.
5. Food and Drug Administration Amendments Act of 2007: Public Law 110-85. US Food and Drug Administration website [Updated 2009 Aug 17; accessed 2011 May 31]. Available from: http://www.fda. gov/RegulatoryInformation/Legislation/ FederalFoodDrugand CosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FoodandDrugAdministrationAmendmentsActof2007/FullTextof FDAAALaw/default.htm
6. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, et al.; International Committee of Medical Journal Editors. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. N Engl J Med 2004;351:1250-1251.
7. AACT database. Clinical Trials Transformation Initiative website [accessed 2012 Mar 21]. Available from: https://www.ctticlinicaltrials. org/project-topics/clinical-trials.gov/aact-database
8. Todd JL, White KR, Chiswell K, Tasneem A, Palmer SM. The current state of clinical trials in pulmonary, critical care, and sleep medicine: a systematic analysis [abstract]. Am J Respir Crit Care Med 2012; 185:A2455.
9. Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, McCourt BJ, Pietrobon R. The database for aggregate analysis of ClinicalTrials gov (AACT) and subsequent regrouping by clinical specialty. PLoS ONE 2012;7:e33677.
10. Introduction to MeSH -2010. US National Library of Medicine website [updated 2011 Aug 1; accessed 2011 Sept 21]. Available from: http://www.nlm.nih.gov/mesh/introduction.html
11. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012;307:1838-1847.
12. Hirsch BR, Califf RM, Cheng SK, Tasneem A, Horton J, Chiswell K, Schulman KA, Dilts DM, Abernethy AP. Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials. gov. JAMA Intern Med 2013;173:972-979.
13. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;294:1255-1259.
14. Peters-Golden M, Klinger JR, Carson SS; ATS Research Advocacy Committee. The case for increased funding for research in pulmonary and critical care. Am J Respir Crit Care Med 2012;186: 213-215.
15. Guidance for industry: chronic obstructive pulmonary disease: developing drugs for treatment. U.S. Food and Drug Administration website [Published 2007 Oct 25; accessed 2012 Mar 12]. Available from: http://www.fda.gov/downloads/ Drugs/GuidanceCompliance RegulatoryInformation/Guidances/ucm071575.pdf.
16. Frequently asked questions. Cystic Fibrosis Foundation website [Updated 2011 Aug 22; accessed 2012 Apr 10]. Available from: http://www.cff.org/AboutCF/ Faqs/
17. Marshall BC, Penland CM, Hazle L, Ashlock M, Wetmore D, Campbell PW III, Beall RJ. Cystic fibrosis foundation: achieving the mission. Respir Care 2009;54:788-795, discussion 795.
18. ClinicalTrials gov a service of the US National Institutes of Health website [updated 2012 Dec 18; accessed 2012 Dec 18]. Available from: http://clinicaltrials.gov/.
19. Schiller JS, Lucas JW, Peregoy JA. Summary health statistics for U.S. adults: National Health Interview Survey, 2011. National Center for Health Statistics. Vital Health Statistics Series 10, Number 256.
20. Hyattsville, MD: U.S. Department of Health and Human Services; 2012.